Abstract:Background Despite the European Society of Cardiology (ESC) guidelines advocating risk prediction models for secondary prevention in established atherosclerotic cardiovascular disease (ASCVD) patients, such models for Japanese individuals remain limited, owing to their comparatively lower ASCVD risk than Western populations. Given this gap, there is a need to develop tailored risk assessment tools for Japanese ASCVD patients to optimize secondary prevention strategies. Purpose Leveraging data from two large-scale, long-term cardiovascular cohorts in Japan, our aim was to develop and externally validate a 10-year risk model predicting recurrent cardiovascular events among patients with established ASCVD. Methods The CHART-2 and Suita studies, large-scale prospective observational multicenter cohort studies in Japan, served as the primary data sources for this investigation. From the CHART-2 study, which comprised 3,560 patients with a history of coronary artery disease or ischemic stroke, we derived our risk model. External validation was conducted using data from the Suita study, which included 445 patients with similar ASCVD backgrounds. The primary outcome of interest was a composite endpoint encompassing cardiovascular death, myocardial infarction, or stroke. Variable selection was performed based on clinically relevant factors previously employed in established risk scores (SMART, REACH, and TRS 2°P risk scores). Logistic regression was utilized for model development, and the predictive performance was assessed using the C-index. Results Over a median follow-up of 10.1 years, the derivation cohort experienced 756 cardiovascular events. Patients in the derivation cohort had an average age of 68.9 ± 10.6 years, with 91% and 24% having a history of coronary artery disease and ischemic stroke, respectively. Using logistic regression, the multivariate model revealed a higher recurrent risk associated with several factors including age, smoking status, systolic blood pressure, diabetes, renal function, number of ASCVD events, atrial fibrillation, lipid levels, left ventricular systolic dysfunction, and statin use. A simple risk score based on these predictors demonstrated a >5-fold gradient of 10-year recurrent risk with a C-index of 0.65 (95% CI 0.63-0.68, Figure). The prediction model was externally validated in the Suita study wit 245 cardiovascular events and a median follow-up of 10.4 years, showing good discriminative ability with a C-index of 0.64 (95% CI 0.60–0.68). Conclusion Our newly developed prediction model offers a valuable tool for identifying individuals at heightened risk of recurrent cardiovascular events over a 10-year period, thereby facilitating more targeted and effective secondary prevention strategies tailored to the unique characteristics of Japanese ASCVD patients.

Validation of Novel Risk Prediction Models in Patients with Brugada Syndrome: A Multicenter Study in Japan

Long-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO (brugada Ablation of VF Substrate Ongoing Multicenter Registry).

Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome

Territory-wide cohort study of Brugada syndrome in Hong Kong: predictors of long-term outcomes using random survival forests and non-negative matrix factorisation

Late life‐threatening arrhythmia in patients with Brugada syndrome: Results from long‐term follow‐up in a large Japanese cohort

A Clinical Score Model to Predict Lethal Events in Young Patients (≤19 Years) With the Brugada Syndrome

Performance of Multiparametric Models in Patients With Brugada Syndrome: A Systematic Review and Meta-Analysis

Nonmodifiable Risk Factors Predict Outcomes in Brugada Syndrome

Prognostic parameters predict cardiac events in Brugada syndrome: a meta-analysis

High‐risk atrioventricular block in Brugada syndrome patients with a history of syncope

Prevalence of Atrial Fibrillation in Patients with Brugada Syndrome in Taiwan

Prediction of 10-year risk for recurrent atherosclerotic cardiovascular events in a secondary prevention population: Insights from CHART-2 and Suita studies in the Japanese population

Genetic Testing in Brugada Syndrome: A 30-Year Experience

Long-term follow-up of patients with Brugada syndrome: Foremost risk factors associated with overall arrhythmic events

Evaluation of the A2B Score for Prediction of Survival in Patients With Heart Failure in a Nationwide Cohort in Japan

Brugada syndrome in Japan and Europe: a genome-wide association study reveals shared genetic architecture and new risk loci

Prediction and Prevention of Sudden Death in the Brugada Syndrome

Ventricular conduction delay as marker of risk in Brugada Syndrome. Results from the analysis of clinical and electrocardiographic features of a large cohort of patients

Temporal Variability in Electrocardiographic Indices in Subjects With Brugada Patterns

Developing a Stroke Risk Prediction Model Using Cardiovascular Risk Factors: The Suita Study

Risk Stratification for the Occurrence of Ventricular Fibrillation in Patients with Early Repolarization Syndrome